There are currently 14 active clinical trials seeking participants for Pulmonary Fibrosis research studies. The states with the highest number of trials for Pulmonary Fibrosis participants are California, Texas, Pennsylvania and New York.
Analysis of Specimens From Individuals With Pulmonary Fibrosis
NCT00084305
Recruiting
The etiology of pulmonary fibrosis is unknown. Analyses of blood, genomic DNA, and specimens procured by bronchoscopy, lung biopsy, lung transplantation, clinically-indicated extra-pulmonary biopsies, or post-mortem examination from individuals with this disorder may contribute to our understanding of the pathogenic mechanisms of pulmonary fibrosis. The purpose of this protocol is to procure and analyze blood, genomic DNA, and specimens by bronchoscopy, lung biopsy, lung transplantation, extra-p... Read More
Gender:
All
Ages:
Between 18 years and 115 years
Trial Updated:
06/19/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pulmonary Fibrosis, Healthy Volunteers, Hermansky-Pudlak Syndrome (HPS)
Register for Updates
Role of Genetic Factors in the Development of Lung Disease
NCT00001532
Recruiting
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers. Optional CT Sub-study The standard CT scan will be compared to the low dose radiation CT s... Read More
Gender:
All
Ages:
Between 2 years and 90 years
Trial Updated:
05/31/2024
Locations: Suburban Hospital, Bethesda, Maryland +1 locations
Conditions: Cystic Fibrosis, Pulmonary Fibrosis, Tuberous Sclerosis, Asthma, Pulmonary Sarcoidosis
Register for Updates
FAPI PET for Lung Fibrosis
NCT05365802
Recruiting
This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease. The study will include patients with interstitial lung disease who have or will initiate a new ILD medication OR will undergo tissue biopsy or surgery of the lung. The study will include 30 p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Interstitial Lung Disease, Idiopathic Interstitial Pneumonias, Drug-Induced Pneumonitis, Hypersensitivity Pneumonitis, Radiation Pneumonitis, Pneumoconiosis, Pulmonary Fibrosis
Register for Updates
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
NCT05180162
Recruiting
This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis. FAP-2286 is a peptide that potently and selectively binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on fibroblasts and has been shown to have higher expression in idiopathic pulmonary fibrosis (IPF), cirrhosis, and cardiac fibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Liver Fibrosis, Pulmonary Fibrosis, Myocardial Fibrosis
Register for Updates
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
NCT04482595
Recruiting
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe COVID-19-related illness and continue to experience post-acute respiratory complications associated with Long-COVID after discharge. Patients will be randomized 1:1 to receive BIO 300 or placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +3 locations
Conditions: Pulmonary Fibrosis, COVID-19, Long COVID, Post-acute Respiratory Complications of COVID-19
Register for Updates
Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19
NCT05387239
Recruiting
The COVID-induced fibrotic lung damage continues long after viral infection has subsided and is exhibited by severe respiratory pathology and concomitant symptoms. The long-lasting sequelae in patients who have recovered from severe COVID indicate that there is a 30% chance of developing a persistent respiratory system pathology and a 10% chance of developing a severe pathology. The symptoms of lung fibrosis include a severe disruption of respiration, reduction of exercise tolerance, and concomi... Read More
Gender:
All
Ages:
Between 25 years and 90 years
Trial Updated:
01/22/2024
Locations: Kit Bartalos, Liberty, Missouri
Conditions: Pulmonary Fibrosis, COVID-19 Respiratory Infection
Register for Updates
Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest
NCT04170062
Recruiting
This study is meant to compare the amount of oxygen required for hypoxemia relief between current standard of care (oxygen only) and oxygen with the addition of high flow air for Chronic Obstructive Pulmonary Disease (COPD), Interstitial Lung Disease (ILD), and Pulmonary Hypertension (PH) patients during rest. Subjects will be titrated from 0 L/min until they maintain 95% SpO2 for each of the following delivery methods: Pulses of pure oxygen (control) Constant high flow air with pulses of pure... Read More
Gender:
All
Ages:
Between 30 years and 100 years
Trial Updated:
01/09/2024
Locations: The Johns Hopkins Hospital, Baltimore, Maryland +1 locations
Conditions: Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Pulmonary Fibrosis, Hypoxemia, Dyspnea, Oxygen Inhalation Therapy
Register for Updates
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
NCT03535545
Recruiting
The goal of this study is to investigate the safety of [68Ga]CBP8 and its efficacy to detect collagen deposition in pulmonary fibrosis.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
12/01/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pulmonary Fibrosis, Lung Cancer
Register for Updates
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
NCT04948203
Recruiting
The primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: University of Chicago, Chicago, Illinois
Conditions: Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Register for Updates
Explanted Lung Tissues With Pulmonary Fibrosis
NCT00515567
Recruiting
The goal of this study is to use the tissues from the explanted lungs in order to better study the cause of pulmonary fibrosis at a cellular level.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: The University of Chicago, Chicago, Illinois
Conditions: Pulmonary Fibrosis
Register for Updates
Interstitial Lung Disease Research Unit Biobank
NCT05392881
Recruiting
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: The University of Kansas Medical Center, Kansas City, Kansas
Conditions: Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Hypersensitivity Pneumonitis
Register for Updates
Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
NCT00258570
Recruiting
The purposes of this study are: to determine if there are specific genetic traits that might explain why patients have developed pulmonary fibrosis; to determine if specific genetic traits account for differing patterns of inflammation and scar tissue that has formed in the patient's lungs.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Pulmonary Fibrosis
Register for Updates